Share of modern (Nasdaq stock code: MRNA) As of 3:24 pm Eastern Standard Time on Wednesday, prices have increased by 9.3%.The biotechnology company announced interim data from an early clinical study that evaluated its personalized cancer vaccine mRNA-4157 and MerckKeytruda for cancer immunotherapy.
Moderna’s interim results come from the extended cohort of its ongoing Phase 1 study, which included 10 HPV-negative head and neck squamous cell carcinoma (HNSCC) and 17 microsatellite stable colorectal cancer (MSS-CRC) patients . Two of the HNSCC patients who received the mRNA-41
The company said that the data obtained so far shows that mRNA-4157 is well tolerated. The adverse events reported in the study are usually low in severity and reversible. The only negative effect of Moderna’s interim results was that no response was observed in MSS-CRC patients who received the mRNA-4157/Keytruda combination.
These results will strengthen investors’ confidence in Moderna’s products other than COVID-19 vaccine candidates. The company also has four other clinical-stage mRNA drug candidates for cancer, including another experimental cancer vaccine in phase 1 testing.
How to do
Moderna will now expand the size of the HNSCC patient cohort in the phase 1 study of mRNA-4157 and Keytruda. However, for biotech companies, the biggest story is still its coronavirus vaccine candidate gene mRNA-1273. Moderna hopes to have enough safety data to urgently apply to the FDA for authorization of the experimental vaccine later this month.